Clinical Trials Logo

Clinical Trial Summary

The current treatment recommendations for P. vivax in pregnant and non-pregnant individuals are to use chloroquine; in non-pregnant patients this is followed by primaquine to prevent relapse. As primaquine can not be used in pregnant women, these women remain at risk of relapse. As there is increasing concern about chloroquine resistant P. vivax in this region, there is a need to identify alternative treatment options. The artemisinin combination therapies are recommended for use against P. falciparum infections in pregnant women after the 1st trimester; additional data are needed to support the use of these drugs against P. vivax.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01107145
Study type Interventional
Source Centers for Disease Control and Prevention
Contact
Status Terminated
Phase Phase 4
Start date February 2011
Completion date January 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04416945 - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic N/A
Recruiting NCT05052502 - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand N/A
Completed NCT00295581 - PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Phase 1
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Completed NCT02001428 - Malaria in Early Life Study N/A
Completed NCT02123290 - DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax Phase 2
Completed NCT01887821 - Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Phase 4
Terminated NCT00138489 - Papua New Guinean Duffy Negativity And Vivax Malar
Not yet recruiting NCT04704999 - Southeast Asia Dose Optimization of Tafenoquine Phase 4
Completed NCT00935623 - Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans Phase 1